MediWound Reports Fourth Quarter and Full-Year 2020 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LVS
7. SAP
8. CSX
9. LRCX
10. MRK

Go back to MediWound Reports Fourth Quarter and Full-Year 2020 Financial Results

MediWound (MDWD) Tops Q4 EPS by 5c, Revenues Beat

February 25, 2021 7:27 AM EST

MediWound (NASDAQ: MDWD) reported Q4 EPS of ($0.06), $0.05 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $6.67 million versus the consensus estimate of $5.59 million.

Fourth Quarter and Full-Year 2020 Business Highlights:

U.S. Food and Drug Administration (FDA) accepted for review the Companys Biologics License Application (BLA) for NexoBrid® and assigned a Prescription Drug User Fee Act (PDUFA) target date of June 29, 2021.BARDA initiated the procurement of NexoBrid for emergency stockpile, valued at $16.5 million, with first deliveries accepted by BARDA in the third and fourth quarters of 2020, with... More